These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 17392719)

  • 1. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants.
    Sjöqvist F; Eliasson E
    Clin Pharmacol Ther; 2007 Jun; 81(6):899-902. PubMed ID: 17392719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
    Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
    Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is pharmacogenetic CYP2D6 testing useful?
    Vetti HH; Molven A; Eliassen AK; Steen VM
    Tidsskr Nor Laegeforen; 2010 Nov; 130(22):2224-8. PubMed ID: 21109842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study.
    Mulder H; Heerdink ER; van Iersel EE; Wilmink FW; Egberts AC
    Ann Pharmacother; 2007 Mar; 41(3):408-13. PubMed ID: 17341534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?
    Jürgens G; Rasmussen HB; Werge T; Dalhoff K; Nordentoft M; Andersen SE
    J Clin Psychopharmacol; 2012 Feb; 32(1):100-5. PubMed ID: 22198443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.
    Rau T; Wohlleben G; Wuttke H; Thuerauf N; Lunkenheimer J; Lanczik M; Eschenhagen T
    Clin Pharmacol Ther; 2004 May; 75(5):386-93. PubMed ID: 15116051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.
    Rodríguez-Antona C; Gurwitz D; de Leon J; Llerena A; Kirchheiner J; de Mesa EG; Ibarreta D
    Pharmacogenomics; 2009 Apr; 10(4):685-99. PubMed ID: 19374522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
    Roberts RL; Mulder RT; Joyce PR; Luty SE; Kennedy MA
    Hum Psychopharmacol; 2004 Jan; 19(1):17-23. PubMed ID: 14716707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2D6 genotypes in Puerto Rican psychiatry patients with intolerance of antidepressants and antipsychotics.
    Gonzalez-Tejera GM; Corey S
    Bol Asoc Med P R; 2009; 101(1):7-12. PubMed ID: 19954080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome P450 2D6 polymorphism and its impact on decision-making in psychopharmacotherapy: finding the right way in an ultrarapid metabolizing patient.
    Paulzen M; Tauber SC; Kirner-Veselinovic A; Gründer G
    J Clin Psychiatry; 2011 Nov; 72(11):1465-7. PubMed ID: 22127193
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacogenetics and psychoactive drug therapy: ready for the patient?
    Steimer W
    Ther Drug Monit; 2010 Aug; 32(4):381-6. PubMed ID: 20526233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.
    Kirchheiner J; Nickchen K; Bauer M; Wong ML; Licinio J; Roots I; Brockmöller J
    Mol Psychiatry; 2004 May; 9(5):442-73. PubMed ID: 15037866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized medicine in psychiatry: new technologies and approaches.
    Costa e Silva JA
    Metabolism; 2013 Jan; 62 Suppl 1():S40-4. PubMed ID: 23018148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidepressant drugs in the elderly--role of the cytochrome P450 2D6.
    Vandel P
    World J Biol Psychiatry; 2003 Apr; 4(2):74-80. PubMed ID: 12692778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical pharmacogenetics in the treatment of schizophrenia].
    Saito M; Yasui-Furukori N; Kaneko S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2005 Jun; 25(3):129-35. PubMed ID: 16045195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics-guided dose modifications of antidepressants.
    Seeringer A; Kirchheiner J
    Clin Lab Med; 2008 Dec; 28(4):619-26. PubMed ID: 19059066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between cytochrome P450-2D6 genotype and prescription of antiparkinsonian drugs in hospitalized psychiatric patients using antipsychotics: a retrospective follow-up study.
    Mulder H; Wilmink FW; Belitser SV; Egberts AC
    J Clin Psychopharmacol; 2006 Apr; 26(2):212-5. PubMed ID: 16633157
    [No Abstract]   [Full Text] [Related]  

  • 18. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
    Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A
    Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. IV. Application of long polymerase chain reaction for identification of CYP2D6 gene duplication.
    Pułczyńska A; Łukaszkiewicz J; Wojnar M; Tomaszewski P; Kubiak-Tomaszewska G; Pachecka J
    Acta Pol Pharm; 2011; 68(1):9-13. PubMed ID: 21485696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant?
    D'Empaire I; Guico-Pabia CJ; Preskorn SH
    J Psychiatr Pract; 2011 Sep; 17(5):330-9. PubMed ID: 21926528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.